Revelstoke Capital Partners has made a significant investment in AOM Infusion, a US-based specialty infusion provider focused on chronic therapy management. No financial terms were disclosed. AOM ...

These conditions are characterized by low immunoglobulin levels and may affect both adults and children. Some of the most ...

Infusion therapy is a medical treatment where fluids, medications, or nutrients are delivered directly into a patient’s ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to ...

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating ...